Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will MR-linac Prove A Turning Point For Radiotherapy And For Elekta?

This article was originally published in Clinica

Executive Summary

Elekta last year set off on what it hoped was a path to recovery, after reporting significantly below-par results for fiscal 2015 under the watch of the then-CEO Niklas Savander. The Swedish cancer treatment specialist unveiled a comprehensive action program and underwent a major executive reshuffle, including the appointment of a new head, Richard Hausmann, formerly chief of GE Healthcare’s MR business.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel